NeuroSense Therapeutics Ltd. (NRSNW) has a negative trailing P/E of -2.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -36.10%, forward earnings yield 1,250.00%.
Criteria proven by this page:
Overall SharesGrow Score: 27/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -18.0 | 0.00 | 24.00 | 0.00 | - |
| 2020 | -7.9 | -0.06 | 33.83 | 0.00 | - |
| 2021 | -6.6 | 0.12 | 2.97 | 0.00 | - |
| 2022 | -1.1 | 0.00 | 2.50 | 0.00 | - |
| 2023 | -1.1 | 0.05 | -5.71 | 0.00 | - |
| 2024 | -2.2 | 0.06 | 8.64 | 0.00 | - |
| 2025 | -1.8 | 0.09 | -12.56 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.63 | $0.00 | $-1.23M | - |
| 2020 | $-1.46 | $0.00 | $-2.83M | - |
| 2021 | $-1.29 | $0.00 | $-2.5M | - |
| 2022 | $-0.97 | $0.00 | $-10.49M | - |
| 2023 | $-0.83 | $0.00 | $-10.11M | - |
| 2024 | $-0.55 | $0.00 | $-10.21M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.32 | $-0.32 – $-0.32 | $714.07K | $714.03K – $714.1K | 1 |
| 2027 | $-0.20 | $-0.20 – $-0.20 | $6.56M | $6.56M – $6.56M | 1 |
| 2028 | $-0.26 | $-0.26 – $-0.26 | $13.38M | $13.38M – $13.38M | 1 |
| 2029 | $2.47 | $2.47 – $2.47 | $360.21M | $360.21M – $360.21M | 1 |
| 2030 | $6.66 | $6.66 – $6.66 | $774.73M | $774.73M – $774.73M | 1 |
